March’s key industry appointments

New appointments

A round-up of the latest senior appointments in the drug discovery sector over the last month.

Julian Collins, Jana Windt and Michiel Stork, ProBioGen

Julian Collins has been appointed as Senior Vice President, Head of People & Organizational Development (P&OD) and a member of the Executive Team. Michiel Stork has taken on a role of Vice President, Business Development (BD) and Jana Windt has filled the position as Head of Marketing & Communications (MarCom).

John A Dawson, Chairman, ViroCell Biologics

John Dawson was Chief Executive Officer of Oxford Biomedica from 2008 to 2022. He has been recognised for his leadership with many awards, including the Scrip Award for Executive of the Year, and the Mediscience Awards CEO of the Year. In 2022, he was awarded a Commander of the Order of the British Empire (CBE) for services to UK Life Science.

Deepak Singh, Vice President of Sales and Marketing, CN Bio

Deepak Singh joins CN Bio from PerkinElmer’s Horizon Discovery where he was Head of Global Commercial. Prior to this, Singh was with Pacific Biosciences as Vice President of EMEA Operations.

Karen Harrison, Chief Operating Officer (Therapeutics Division), Avacta

Karen Harrison joins Avacta with over 30 years’ experience managing complex global B2C organisations. Within the last 15 years, she has undertaken senior positions predominantly within the healthcare and life sciences sectors, including Vice President for Talent at Astellas Pharma.

Linda De Jesus, Global VP and General Manager of Commercial, Integrated DNA Technologies

Linda De Jesus brings over 20 years of international life sciences leadership experience from her diverse career in general management and commercial functions with a track record of successful execution for high-growth businesses spanning pharmaceutical, biopharma, biotechnology and academia.

Craig Blanchette and Michael Wolfe, Switch Therapeutics

Dr Craig Blanchette joins as Senior Vice President, Research. Most recently, Dr Blanchette led a large drug discovery department at Genentech.

Michael Wolfe has been appointed Senior Vice President, Finance and Operations. Most recently, he served in roles of increasing responsibility at Kezar Life Sciences (Kezar).

James Borneman, Chief Operating Officer, Bryn Pharma

James Borneman has experience across many technical, operational, and commercial roles. He most recently led the integration of a multi-billion-dollar acquisition as Head of the Kadmon Integration office at Sanofi.

Vivian DeWoskin, Chief Commercial Officer, NeuraLight

Most recently, DeWoskin served as VP, Head of Strategy at Komodo Health, a software company. Before that, DeWoskin spent eight years at Trinity Life Sciences, a company that provides insights & analytics to pharma and emerging biotech companies.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free